Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東羅欣藥業集團股份有限公司 SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.*

(a joint stock limited company established in the People's Republic of China with limited liability)

(Stock Code: 8058)

ANNOUNCEMENT POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board is pleased to announce that the resolutions as set out in the Notice (as defined below) dated 10 April 2017 were duly passed at the AGM held on 29 May 2017.

POLL RESULTS OF THE AGM

References are made to the notice of the AGM (the "Notice") of Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (the "Company") dated 10 April 2017. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as defined in the Notice.

The Board is pleased to announce that the resolutions as set out in the Notice dated 10 April 2017 were duly passed by way of poll at the AGM which was held at Conference Room, Level 3, Administrative Centre, Luoqi Road, Linyi High and New Technology Industries Development Zone, Shandong Province, the PRC on 29 May 2017.

As at the date of the AGM, the Company had issued a total of 609,600,000 Shares, comprising 164,560,000 H Shares and 445,040,000 Domestic Shares. The total number of Shares entitling the Shareholders to attend and vote for or against the resolutions at the AGM were 609,600,000 Shares.

There were no Shares entitling the Shareholders to attend and abstain from voting in favour of any resolution at the AGM as set out in Rule 17.47A of the GEM Listing Rules and there were no Shares requiring the Shareholders to abstain from voting at the AGM under the GEM Listing Rules.

^{*} For identification purpose only

The H Share registrar of the Company, Computershare Hong Kong Investor Services Limited (香港中央證券登記有限公司) was appointed as scrutineer for the vote-taking at the AGM.

THE AGM

At the AGM, Shareholders or their proxies holding 525,044,138 Shares with voting right, representing 86.13% of the entire issued share capital of the Company, were present and constituted a quorum for the AGM in accordance with the articles of association of the Company and the Company Law of the PRC.

The Board is pleased to announce that the resolutions as set out in the Notice were duly passed at the AGM, the poll results of which are as follows:

Ordinary resolutions		Number of Votes Cast (%)		
		For	Against	Abstain
1.	to consider and approve the audited financial statements of the Company and the reports of the board (the "Board") of directors (the "Directors") and the auditors of the Company for the year ended 31 December 2016;	522,556,138 (100%)	0 (0%)	2,488,000
2.	to consider and approve the report of the supervisors of the Company for the year ended 31 December 2016;	522,556,138 (100%)	0 (0%)	2,488,000
3.	to consider and approve the Board to fix the remunerations of the Directors and supervisors of the Company;	520,182,138 (99.91%)	462,000 (0.09%)	2,738,000
4.	to consider and approve the appointment of HLB Hodgson Impey Cheng Limited as the auditors of the Company and to authorise the Board to fix their remuneration;	521,344,138 (99.86%)	750,000 (0.14%)	2,950,000
5.	to re-elect Mr. Fu Hongzheng (付宏征) as an independent non-executive Director; and	519,067,070 (99.33%)	3,489,068 (0.67%)	2,488,000
6.	to re-elect Mr. Foo Tin Chung, Victor (傅天忠) as an independent non-executive Director.	518,865,821 (99.29%)	3,690,317 (0.71%)	2,488,000

As more than one-half of the votes were cast in favour of each of the resolutions at the AGM, all resolutions as set out in the Notice were duly passed as ordinary resolutions of the Company.

By order of the Board

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.*

Liu Baoqi

Chairman

The PRC, 29 May 2017

As at the date of this announcement, the Board comprises 10 Directors, of which Mr. Liu Baoqi (劉保起), Ms. Li Minghua (李明華), Mr. Han Fengsheng (韓風生), Mr. Chen Yu (陳雨) and Mr. Liu Zhenteng (劉振騰) are executive Directors; Mr. Liu Zhenhai (劉振海) is a non-executive Director; Mr. Foo Tin Chung, Victor (傅天忠), Mr. Fu Hongzheng (付宏征), Prof. Du Guanhua (杜冠華) and Ms. Huang Huiwen (黃慧文) are independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company's designated website at: http://shandongluoxin.quamir.com.

* For identification purpose only